Voyager Therapeutics (VYGR) EBIT (2014 - 2026)

Voyager Therapeutics has disclosed EBIT across 13 years of filings, most recently posting -$30.3 million for Q1 2026.

• EBIT for Q1 2026 came in at -$30.3 million, up 12.75% year-over-year; the trailing twelve-month figure through Mar 2026 was -$127.4 million (down 25.17% YoY), and the FY2025 annual result was -$131.8 million, down 58.3% from the prior year.
• EBIT came in at -$30.3 million for Q1 2026 at Voyager Therapeutics, down from -$29.9 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $122.9 million in Q1 2023 to a low of -$39.9 million in Q4 2023.
• The 5-year median for EBIT is -$25.4 million (2023), against an average of -$15.8 million.
• Across the five-year window, EBIT slumped 530.78% in 2022 and soared 675.57% in 2023, its largest moves.
• Voyager Therapeutics' EBIT stood at -$24.6 million in 2022, then tumbled by 62.3% to -$39.9 million in 2023, then advanced by 3.93% to -$38.3 million in 2024, then climbed by 21.85% to -$29.9 million in 2025, then slipped by 1.13% to -$30.3 million in 2026.
• The last three EBIT figures came in at -$30.3 million (Q1 2026), -$29.9 million (Q4 2025), and -$30.6 million (Q3 2025), per Business Quant data.